Processa Pharmaceuticals, Inc. Proceeds from (Repurchase of) Equity
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from (Repurchase of) Equity of -$300.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepurchaseOfEquity · last filed 2022-11-08
- Processa Pharmaceuticals, Inc. proceeds from (repurchase of) equity for the quarter ending 2022-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from (repurchase of) equity for the quarter ending 2022-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from (repurchase of) equity for the quarter ending 2022-03-31 was -$300.00K.
| Period end | Proceeds from (Repurchase of) Equity 3 month | Proceeds from (Repurchase of) Equity 6 month | Proceeds from (Repurchase of) Equity 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | -$300.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$300.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$300.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |